Cancer statistics, 1999, Cancer statistics, pp.8-31, 1999. ,
DOI : 10.3322/canjclin.49.1.8
Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities, Nature Reviews Cancer, vol.2, issue.8, pp.584-93, 2002. ,
DOI : 10.1038/nrc867
Morphometric Evidence for Bone Resorption and Replacement in Prostate Cancer, British Journal of Urology, vol.3, issue.Suppl. 1, pp.74-80, 1991. ,
DOI : 10.1111/j.1464-410X.1991.tb15260.x
Markers of bone turnover for the management of patients with bone metastases from prostate cancer, British Journal of Cancer, vol.82, issue.4, pp.858-64, 2000. ,
DOI : 10.1054/bjoc.1999.1012
Prostate cancer mediates osteoclastogenesis through two different pathways, Cancer Lett, vol.223, pp.121-129, 2005. ,
Osteoprotegerin inhibits prostate cancer???induced osteoclastogenesis and prevents prostate tumor growth in the bone, Journal of Clinical Investigation, vol.107, issue.10, pp.1235-1279, 2001. ,
DOI : 10.1172/JCI11685
Soluble receptor activator of nuclear factor ?B Fc diminishes prostate cancer progression in bone, Cancer Res, vol.63, pp.7883-90, 2003. ,
Osteoprotegerin in Prostate Cancer Bone Metastasis, Cancer Research, vol.65, issue.5, pp.1710-1718, 2005. ,
DOI : 10.1158/0008-5472.CAN-04-2033
The effects of RANK blockade and osteoclast depletion in a model of pure osteoblastic prostate cancer metastasis in bone, Journal of Orthopaedic Research, vol.63, issue.6, pp.1475-83, 2005. ,
DOI : 10.1016/j.orthres.2005.05.004.1100230634
The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling, Cytokine & Growth Factor Reviews, vol.15, issue.6, pp.457-75, 2004. ,
DOI : 10.1016/j.cytogfr.2004.06.004
Receptor activator of nuclear factor-??B ligand and osteoprotegerin, Cancer, vol.3, issue.Suppl 1, pp.460-70, 2001. ,
DOI : 10.1002/1097-0142(20010801)92:3<460::AID-CNCR1344>3.0.CO;2-D
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis, Nature, vol.397, pp.315-338, 1999. ,
The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature Osteoclasts, The Journal of Cell Biology, vol.108, issue.3, pp.327-365, 1999. ,
DOI : 10.1016/0006-291X(89)91143-1
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell, vol.93, pp.165-76, 1998. ,
Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand ,
OPG: new therapeutic targets in bone tumors and associated osteolysis ,
Osteoprotegerin and rank ligand expression in prostate cancer, Urology, vol.57, issue.4, pp.611-617, 2001. ,
DOI : 10.1016/S0090-4295(00)01122-5
Serum osteoprotegerin levels are increased in patients with advanced prostate cancer, Clin Cancer Res, vol.7, pp.2977-83, 2001. ,
Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells, Cancer Res, vol.62, pp.1619-1642, 2002. ,
RANK is the essential signaling receptor for osteoclast differentiation factor in osteoclastogenesis, Biochem Biophys Res Commun, vol.253, pp.395-400, 1998. ,
RANKL directly induces bone morphogenetic protein-2 expression in RANK-expressing POS-1 osteosarcoma cells, International Journal of Oncology ,
DOI : 10.3892/ijo.28.1.261
URL : https://hal.archives-ouvertes.fr/inserm-00667510
Molecular Mechanisms of Tumor-Bone Interactions in Osteolytic Metastases, Critical Reviews?? in Eukaryotic Gene Expression, vol.10, issue.2, pp.159-78, 2000. ,
DOI : 10.1615/CritRevEukarGeneExpr.v10.i2.50
Tumor-bone cellular interactions in skeletal metastases, J Musculoskelet Neuronal Interact, vol.4, pp.308-326, 2004. ,
Transforming Growth Factor-Beta in Osteolytic Breast Cancer Bone Metastases, Clinical Orthopaedics and Related Research, vol.415, pp.32-40, 2003. ,
DOI : 10.1097/01.blo.0000093055.96273.69
Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill, Journal of Immunological Methods, vol.119, issue.2, pp.203-213, 1989. ,
DOI : 10.1016/0022-1759(89)90397-9
Downregulation of Osteoblast Markers and Induction of the Glial Fibrillary Acidic Protein by Oncostatin M in Osteosarcoma Cells Require PKC?? and STAT3, Journal of Bone and Mineral Research, vol.100, issue.Suppl, pp.1850-61, 2004. ,
DOI : 10.1359/JBMR.040817
An in vivo model of prostate carcinoma growth and invasion in bone, Cell and Tissue Research, vol.307, issue.3, pp.337-382, 2002. ,
DOI : 10.1007/s00441-001-0503-x
Regulation of cancer cell migration and bone metastasis by RANKL, Nature, vol.440, pp.692-698, 2006. ,
Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts, Biochemical and Biophysical Research Communications, vol.305, issue.2, pp.211-215, 2003. ,
DOI : 10.1016/S0006-291X(03)00695-8
The vicious cycle of bone metastases, J Musculoskelet Neuronal Interact, vol.2, pp.570-572, 2002. ,
Oscillatory fluid flow-induced shear stress decreases osteoclastogenesis through RANKL and OPG signaling, Bone, vol.39, issue.5, 2006. ,
DOI : 10.1016/j.bone.2006.05.017
IL-6, RANKL, TNF-alpha/IL-1: interrelations in bone resorption pathophysiology, Cytokine Growth Factor Rev, vol.15, pp.49-60, 2004. ,
Interleukin-6: An osteotropic factor influencing bone formation?, Bone, vol.37, issue.5, pp.601-607, 2005. ,
DOI : 10.1016/j.bone.2005.06.002
Dexamethasone enhances expression of membrane and soluble interleukin-6 receptors by prostate carcinoma cell lines, Anticancer Res, vol.18, pp.4403-4411, 1998. ,
Characterization of the role of IL-6 in the progression of prostate cancer, The Prostate, vol.55, issue.3, pp.199-207, 1999. ,
DOI : 10.1002/(SICI)1097-0045(19990215)38:3<199::AID-PROS4>3.0.CO;2-H
Interleukin-6 and prostate cancer progression, Cytokine & Growth Factor Reviews, vol.12, issue.1, pp.33-40, 2001. ,
DOI : 10.1016/S1359-6101(00)00021-6
The distrubution of secondary growths in cancer of the breast, Lancet, vol.1, pp.571-573, 1889. ,
Expression of receptor activator of nuclear factor-kappaB is inversely correlated with metastatic phenotype in breast carcinoma, Clin Cancer Res, vol.11, pp.162-167, 2005. ,